Therapeutic breakthroughs for metastatic thyroid cancer
Authors:
- 1 February 2020
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 16 (2) , 77-78
Abstract
Multikinase inhibitors are effective treatments for thyroid cancers, acting primarily as antiangiogenic agents. This year, advances have been made in selective targeting of RET and BRAF in patients with medullary and anaplastic thyroid cancers, respectively. However, Hürthle cell carcinomas have a unique genomic landscape with no dominant truncal drivers, precluding simplistic approaches to therapeutic targeting.Keywords
This publication has 9 references indexed in Scilit:
- Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
BRAF
V600E
-Mutated Anaplastic Thyroid CarcinomaThyroid®, 2019
- Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.Journal of Clinical Oncology, 2019
- Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal LandscapesCancer Cell, 2018
- Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell CarcinomaCancer Cell, 2018
- Precision Targeted Therapy with BLU-667 for RET-Driven CancersCancer Discovery, 2018
- Selective RET kinase inhibition for patients with RET-altered cancersAnnals of Oncology, 2018
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid CancerJournal of Clinical Oncology, 2018
- Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.Journal of Clinical Oncology, 2017
- Biologic and Clinical Perspectives on Thyroid CancerNew England Journal of Medicine, 2016